FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for EYLEA HD, a high-dose formulation of aflibercept, expanding the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema Following Retinal Vein Occlusion
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA HD (aflibercept)

Snippet

SUPPL AP for EYLEA HD (AFLIBERCEPT)